[1]
|
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases
Journal of Pharmacokinetics and Pharmacodynamics,
2023
DOI:10.1007/s10928-023-09876-6
|
|
|
[2]
|
Conceptual and organizational barriers to quantitative systems pharmacology modeling of pathophysiological systemic drug hypotheses
CPT: Pharmacometrics & Systems Pharmacology,
2022
DOI:10.1002/psp4.12873
|
|
|
[3]
|
Conceptual and organizational barriers to quantitative systems pharmacology modeling of pathophysiological systemic drug hypotheses
CPT: Pharmacometrics & Systems Pharmacology,
2022
DOI:10.1002/psp4.12873
|
|
|
[4]
|
Conceptual and organizational barriers to quantitative systems pharmacology modeling of pathophysiological systemic drug hypotheses
CPT: Pharmacometrics & Systems Pharmacology,
2022
DOI:10.1002/psp4.12873
|
|
|
[5]
|
Toward Predicting Impact of Common Genetic Variants on Schizophrenia Clinical Responses With Antipsychotics: A Quantitative System Pharmacology Study
Frontiers in Neuroscience,
2021
DOI:10.3389/fnins.2021.738903
|
|
|
[6]
|
Exploring the relation between BOLD fMRI and cognitive performance using a computer-based quantitative systems pharmacology model: Applications to the COMTVAL158MET genotype and ketamine
European Neuropsychopharmacology,
2021
DOI:10.1016/j.euroneuro.2021.04.001
|
|
|
[7]
|
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data
Clinical Pharmacology & Therapeutics,
2020
DOI:10.1002/cpt.1782
|
|
|
[8]
|
Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach
Alzheimer's & Dementia,
2020
DOI:10.1002/alz.12082
|
|
|
[9]
|
Salvaging CNS Clinical Trials Halted Due to COVID‐19
CPT: Pharmacometrics & Systems Pharmacology,
2020
DOI:10.1002/psp4.12535
|
|
|
[10]
|
Therapeutic modulators of the serotonin 5-HT4 receptor: a patent review (2014-present)
Expert Opinion on Therapeutic Patents,
2020
DOI:10.1080/13543776.2020.1767587
|
|
|
[11]
|
Simulating the Effects of Common Comedications and Genotypes on Alzheimer’s Cognitive Trajectory Using a Quantitative Systems Pharmacology Approach
Journal of Alzheimer's Disease,
2020
DOI:10.3233/JAD-200688
|
|
|
[12]
|
A modeling informed quantitative approach to salvage clinical trials interrupted due to COVID‐19
Alzheimer's & Dementia: Translational Research & Clinical Interventions,
2020
DOI:10.1002/trc2.12053
|
|
|
[13]
|
Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach
Alzheimer's & Dementia,
2020
DOI:10.1002/alz.12082
|
|
|
[14]
|
Salvaging CNS Clinical Trials Halted Due to COVID‐19
CPT: Pharmacometrics & Systems Pharmacology,
2020
DOI:10.1002/psp4.12535
|
|
|
[15]
|
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data
Clinical Pharmacology & Therapeutics,
2020
DOI:10.1002/cpt.1782
|
|
|
[16]
|
Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities
CPT: Pharmacometrics & Systems Pharmacology,
2019
DOI:10.1002/psp4.12463
|
|
|
[17]
|
Neuronal Circuit-Based Computer Modeling as a Phenotypic Strategy for CNS R&D
Frontiers in Neuroscience,
2019
DOI:10.3389/fnins.2019.00723
|
|
|
[18]
|
Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities
CPT: Pharmacometrics & Systems Pharmacology,
2019
DOI:10.1002/psp4.12463
|
|
|
[19]
|
Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model
Alzheimer's Research & Therapy,
2018
DOI:10.1186/s13195-018-0343-5
|
|
|
[20]
|
Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases
Expert Review of Clinical Pharmacology,
2018
DOI:10.1080/17512433.2018.1501555
|
|
|
[21]
|
Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare
Journal of Psychopharmacology,
2018
DOI:10.1177/0269881118796809
|
|
|
[22]
|
Semi-mechanistic computer simulation of psychotic symptoms in schizophrenia with a model of a humanized cortico-striatal-thalamocortical loop
European Neuropsychopharmacology,
2017
DOI:10.1016/j.euroneuro.2016.12.006
|
|
|
[23]
|
Modulating 5-HT4 and 5-HT6 receptors in Alzheimer’s disease treatment
Future Medicinal Chemistry,
2017
DOI:10.4155/fmc-2017-0031
|
|
|
[24]
|
Knowledge‐driven computational modeling in Alzheimer's disease research: Current state and future trends
Alzheimer's & Dementia,
2017
DOI:10.1016/j.jalz.2017.08.011
|
|
|
[25]
|
Towards the virtual human patient. Quantitative Systems Pharmacology in Alzheimer's disease
European Journal of Pharmacology,
2017
DOI:10.1016/j.ejphar.2017.05.062
|
|
|
[26]
|
Knowledge‐driven computational modeling in Alzheimer's disease research: Current state and future trends
Alzheimer's & Dementia,
2017
DOI:10.1016/j.jalz.2017.08.011
|
|
|
[27]
|
Big data to smart data in Alzheimer's disease: Real‐world examples of advanced modeling and simulation
Alzheimer's & Dementia,
2016
DOI:10.1016/j.jalz.2016.05.005
|
|
|
[28]
|
Big data to smart data in Alzheimer's disease: Real‐world examples of advanced modeling and simulation
Alzheimer's & Dementia,
2016
DOI:10.1016/j.jalz.2016.05.005
|
|
|
[29]
|
Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge
Alzheimer's & Dementia,
2016
DOI:10.1016/j.jalz.2016.04.008
|
|
|
[30]
|
Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge
Alzheimer's & Dementia,
2016
DOI:10.1016/j.jalz.2016.04.008
|
|
|
[31]
|
A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson’s Disease
Frontiers in Pharmacology,
2016
DOI:10.3389/fphar.2016.00006
|
|
|
[32]
|
The promises of quantitative systems pharmacology modelling for drug development
Computational and Structural Biotechnology Journal,
2016
DOI:10.1016/j.csbj.2016.09.002
|
|
|
[33]
|
Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology
Frontiers in Pharmacology,
2015
DOI:10.3389/fphar.2015.00198
|
|
|
[34]
|
Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: Application to iloperidone
Journal of Psychopharmacology,
2015
DOI:10.1177/0269881114568042
|
|
|
[35]
|
Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery
Future Medicinal Chemistry,
2015
DOI:10.4155/fmc.15.143
|
|
|
[36]
|
Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward
Future Medicinal Chemistry,
2014
DOI:10.4155/fmc.14.97
|
|
|
[37]
|
A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance
Frontiers in Pharmacology,
2014
DOI:10.3389/fphar.2014.00229
|
|
|